Amwell expects Q4 2026 revenue of $48M-$50M and adjusted EBITDA from breakeven to $1M
Tickers: $AMWL
Topics: EBITDA guidance financial outlook revenue guidance
Read the full article at Seeking Alpha
Part of the story Tandem Diabetes Care Reports Q3 2026 Growth Driven by International Expansion and Mobi Platform (6 articles)